Breaking News Instant updates and real-time market news.

VRX

Valeant

$22.24

-0.53 (-2.33%)

12:55
10/14/16
10/14
12:55
10/14/16
12:55

Valeant announces price raises of 2%-9% in certain portfolios

Valeant Pharmaceuticals announced that the company's Patient Access and Pricing Committee has made decisions regarding price changes of products in the company's neurology, GI and urology portfolios. The planned wholesale acquisition price changes, effective October 14, range from 2% to 9%. "The changes are aligned with the Committee's commitment that the average annual price increase for Valeant's prescription pharmaceutical products will be set at no greater than single digits and below the 5-year weighted average of the increases within the branded biopharmaceutical industry," the company said in a statement. Valeant added that its 2016 pricing actions across its U.S. branded Rx portfolio, represent an increase of less than 2.0% within the calendar 2016 year. On a forward looking annualized basis, 2016 price actions are in line with 2016 Consumer Price Index of 2.3%, it explained. "In 2016, net pricing of Valeant's Dermatology and Ophthalmology products, after taking into account the impact of rebates and other adjustments, will have decreased by greater than 10% on average. There will be no pricing adjustments this year on Dermatology and Ophthalmology products," Valeant stated. Joseph Papa, Valeant CEO, said, "In reviewing product pricing, the Committee considers overall market dynamics along with the impact of any price increase on patients, doctors, and our health care industry partners. We believe the actions announced today are consistent with our commitment to ensure that patients continue to have access to the medicines they need at an affordable price and demonstrate that we are taking our approach to responsible pricing seriously."

  • 16

    Nov

  • 14

    Dec

VRX Valeant
$22.24

-0.53 (-2.33%)

09/19/16
WELS
09/19/16
NO CHANGE
WELS
Price increases could be negative sign, says Wells Fargo
After Valeant increased the list prices of three of its products with combined sales of $1.2M last year, Wells Fargo says further price increases could be forthcoming, and the price increases could indicate that the company feels it needs to raise prices to meet its 2H16 guidance. Noting that the company raised the list price on each of the products by 9.9%, Wells believes that the company could have raised prices by that amount instead of 10% to "stay under the radar of managed care plans and states" looking to prevent double digit price increases. Wells keeps an Underperform rating on the stock.
09/20/16
DBAB
09/20/16
INITIATION
Target $30
DBAB
Hold
Valeant reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert reinstated coverage of Valeant Pharmaceuticals with a Hold rating and $30 price target. Potential fines from the numerous investigations into the company are difficult to predict, Gilbert tells investors in a research note. The analyst assumes revenue for Valeant's dermatology business will begin to rebound in the second half of 2016 and into 2017. Before restricting coverage on the name, Deutsche had a Hold rating on the shares.
09/23/16
WELS
09/23/16
NO CHANGE
WELS
Underperform
Wells thinks Valeant's $1B acquisition in 2015 could be worth $50M or less
Wells Fargo analyst David Maris believes Valeant Pharmaceuticals will take a large impairment charge on the carrying value of Sprout, perhaps as much as 90% of its value. Sprout won approval in 2015 for Addyi, the first pill to aid a woman's sex drive. Valeant bought Sprout for $1B in August 2015, and in December 2015 forecasted sales of $100M-$150M, Maris points out. With sales in July, according to IMS, reaching only $696,235, Maris thinks Addyi "has no chance" of reaching $100M in 2016 and "might not even reach" $10M. He believes Sprout may be worth $50M or less. Without an add-back to adjusted earnings going forward, the [potential write-off would have a 14c per share impact to annual adjusted earnings in 2017 and beyond, Maris tells investors in a research note. Further, he believes Valeant could have other assets with this same problem, compounding the company's divestiture plans. Maris keeps an Underperform rating on Valeant with a $17-$22 price target range. The drugmaker closed yesterday down 12c to $26.85.
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Underperform
Valeant legal woes may present bigger risk than realized, says Wells Fargo
Wells Fargo analyst David Maris said in a new note to investors that he continues to think investors are underestimating the potential downside posed by Valeant's legal troubles, whose stakes "might not be in the tens of millions, but much larger." Maris, who has kept an Underperform rating on Valeant Pharmaceuticals (VRX) since starting coverage of the stock in February, notes that the company has not taken any reserves for Allergan (AGN) or Philidor-related litigation.

TODAY'S FREE FLY STORIES

MRCY

Mercury Systems

$48.29

0.84 (1.77%)

16:33
09/19/17
09/19
16:33
09/19/17
16:33
Hot Stocks
Mercury Systems receives $3.8M order for advanced electronic warfare application »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HF

HFF Inc.

$37.12

0.12 (0.32%)

16:30
09/19/17
09/19
16:30
09/19/17
16:30
Hot Stocks
HFF Inc. announces sale of office in Raleigh-Durham, NC for $105.5M »

Holliday Fenoglio Fowler…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/19/17
09/19
16:30
09/19/17
16:30
Options
Preliminary option volume of 13.8M today »

Preliminary option volume…

RYAM

Rayonier Advanced Materials

16:30
09/19/17
09/19
16:30
09/19/17
16:30
Hot Stocks
Rayonier Advanced Materials estimates impact from Hurricane Irma »

Rayonier Advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALOG

Analogic

$75.95

-1.35 (-1.75%)

16:28
09/19/17
09/19
16:28
09/19/17
16:28
Earnings
Analogic sees FY18 EPS $2.70 to $2.90, two estimates consensus $2.80 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

, TMUS

T-Mobile

$65.42

3.62 (5.86%)

16:28
09/19/17
09/19
16:28
09/19/17
16:28
General news
On The Fly: Top stock stories for Tuesday »

Stocks searched for a…

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

TMUS

T-Mobile

$65.42

3.62 (5.86%)

S

Sprint

$8.20

0.52 (6.77%)

VZ

Verizon

$49.34

1.25 (2.60%)

SFTBF

SoftBank

$82.75

4.45 (5.68%)

DTEGY

Deutsche Telekom

$18.75

0.68 (3.76%)

BOBE

Bob Evans

$77.41

4.48 (6.14%)

POST

Post Holdings

$86.36

0.52 (0.61%)

RAD

Rite Aid

$2.40

-0.33 (-12.09%)

WBA

Walgreens Boots Alliance

$81.21

-1.39 (-1.68%)

KSS

Kohl's

$45.38

0.49 (1.09%)

AZO

AutoZone

$535.19

-28.21 (-5.01%)

SNCR

Synchronoss

$9.82

-6.93 (-41.37%)

REV

Revlon

$17.05

1.05 (6.56%)

BBY

Best Buy

$52.76

-4.59 (-8.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

  • 09

    Nov

  • 16

    May

FDX

FedEx

$216.00

0.92 (0.43%)

16:26
09/19/17
09/19
16:26
09/19/17
16:26
Earnings
FedEx sees FY18 ex-items EPS $12.00-$12.80, consensus $13.38 »

The company is lowering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

CSTM

Constellium

$10.00

0.4 (4.17%)

16:26
09/19/17
09/19
16:26
09/19/17
16:26
Hot Stocks
Constellium signs contract with Pilatus to support jet aircraft program »

Constellium announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 02

    Oct

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

16:25
09/19/17
09/19
16:25
09/19/17
16:25
Conference/Events
Gemphire Therapeutics to hold a conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

SERV

ServiceMaster

$47.06

0.1 (0.21%)

16:23
09/19/17
09/19
16:23
09/19/17
16:23
Initiation
ServiceMaster initiated  »

ServiceMaster initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSC

Harsco

$19.90

0.4 (2.05%)

16:22
09/19/17
09/19
16:22
09/19/17
16:22
Hot Stocks
Harsco gets orders from D.C and Sacramento, CA for safety systems »

Harsco Corporation's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

SBRA

Sabra Health Care

$22.97

-0.47 (-2.01%)

, TPGI

Now owned by PKY

16:22
09/19/17
09/19
16:22
09/19/17
16:22
Hot Stocks
Sabra to acquire 49% equity interest in senior housing managed by Enlivant »

Sabra Health Care,…

SBRA

Sabra Health Care

$22.97

-0.47 (-2.01%)

TPGI

Now owned by PKY

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SBRA

Sabra Health Care

$22.97

-0.47 (-2.01%)

, TPGI

Now owned by PKY

16:22
09/19/17
09/19
16:22
09/19/17
16:22
Hot Stocks
Sabra to acquire 49% equity interest in senior housing managed by Enlivant »

Sabra Health Care,…

SBRA

Sabra Health Care

$22.97

-0.47 (-2.01%)

TPGI

Now owned by PKY

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BBBY

Bed Bath & Beyond

16:21
09/19/17
09/19
16:21
09/19/17
16:21
Hot Stocks
Bed Bath & Beyond reports Q2 SSS from customer-facing digital channels up 20%+ »

Comparable sales from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:20
09/19/17
09/19
16:20
09/19/17
16:20
Hot Stocks
Bed Bath & Beyond sees over $150M in savings from transformational initiatives »

The company believes the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:20
09/19/17
09/19
16:20
09/19/17
16:20
Hot Stocks
Bed Bath & Beyond repurchased about $56M of common stock in Q2 »

During the fiscal 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

FDX

FedEx

$216.00

0.92 (0.43%)

16:19
09/19/17
09/19
16:19
09/19/17
16:19
Earnings
FedEx reports Q1 adjusted EPS $2.51, consensus $3.09 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

ALOG

Analogic

$75.95

-1.35 (-1.75%)

16:18
09/19/17
09/19
16:18
09/19/17
16:18
Earnings
Analogic reports Q4 EPS 0c, two estimate consensus 50c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:18
09/19/17
09/19
16:18
09/19/17
16:18
Earnings
Bed Bath & Beyond sees FY17 EPS about $3.00, consensus $4.01 »

The Company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

$NSD

NASDAQ Market Internals

16:17
09/19/17
09/19
16:17
09/19/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:16
09/19/17
09/19
16:16
09/19/17
16:16
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BBBY

Bed Bath & Beyond

16:16
09/19/17
09/19
16:16
09/19/17
16:16
Earnings
Bed Bath & Beyond reports Q2 EPS 67c including charges, consensus 95c »

Reports Q2 revenue $2.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

$NYE

NYSE Market Internals

16:16
09/19/17
09/19
16:16
09/19/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$38.97

-0.41 (-1.04%)

16:15
09/19/17
09/19
16:15
09/19/17
16:15
Syndicate
Acceleron announces $150M common stock offering »

Acceleron Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

PSTG

Pure Storage

$14.71

0.06 (0.41%)

, CSCO

Cisco

$32.49

-0.03 (-0.09%)

16:15
09/19/17
09/19
16:15
09/19/17
16:15
Periodicals
Pure Storage said to be trying to find buyer, Barron's reports »

Summit Redstone's…

PSTG

Pure Storage

$14.71

0.06 (0.41%)

CSCO

Cisco

$32.49

-0.03 (-0.09%)

IBM

IBM

$144.41

-0.145 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Sep

  • 22

    Sep

  • 23

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 22

    Oct

  • 15

    Nov

  • 15

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.